bioAffinity Technologies, Inc.
BIAF
$3.88
-$0.12-3.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.16M | 6.78M | 7.68M | 8.81M | 9.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.16M | 6.78M | 7.68M | 8.81M | 9.36M |
| Cost of Revenue | 4.23M | 4.89M | 5.39M | 5.78M | 5.98M |
| Gross Profit | 1.94M | 1.89M | 2.29M | 3.03M | 3.38M |
| SG&A Expenses | 9.91M | 9.80M | 9.95M | 10.21M | 9.94M |
| Depreciation & Amortization | 504.90K | 534.80K | 572.70K | 610.60K | 605.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.73M | 17.16M | 17.74M | 18.44M | 18.32M |
| Operating Income | -10.57M | -10.38M | -10.06M | -9.64M | -8.95M |
| Income Before Tax | -14.87M | -14.70M | -11.65M | -9.72M | -9.03M |
| Income Tax Expenses | 44.10K | 40.90K | 40.30K | 16.70K | 11.70K |
| Earnings from Continuing Operations | -14.91 | -14.74 | -11.69 | -9.74 | -9.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.91M | -14.74M | -11.69M | -9.74M | -9.04M |
| EBIT | -10.57M | -10.38M | -10.06M | -9.64M | -8.95M |
| EBITDA | -10.07M | -9.85M | -9.49M | -9.02M | -8.35M |
| EPS Basic | -15.42 | -20.73 | -20.84 | -21.33 | -22.35 |
| Normalized Basic EPS | -9.60 | -12.92 | -12.99 | -13.31 | -13.95 |
| EPS Diluted | -15.42 | -20.73 | -20.84 | -21.33 | -22.35 |
| Normalized Diluted EPS | -9.60 | -12.92 | -12.99 | -13.31 | -13.95 |
| Average Basic Shares Outstanding | 6.88M | 2.90M | 2.25M | 1.83M | 1.62M |
| Average Diluted Shares Outstanding | 6.88M | 2.90M | 2.25M | 1.83M | 1.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |